NCT06697990View on ClinicalTrials.gov

Cerebrospinal Fluid Immune Microenvironment Mechanism in Anaplastic Lymphoma Kinase Positive Lung Cancer Patients

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 1, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

March 31, 2026

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

DRUG

Iruplinalib

60 mg of Iruplinalib, once daily for 7 days, followed by 180 mg of Iruplinalib, once daily in a 28-days cycle.

All Listed Sponsors

lead

Tianjin Medical University Cancer Institute and Hospital

OTHER

NCT06697990 - Cerebrospinal Fluid Immune Microenvironment Mechanism in Anaplastic Lymphoma Kinase Positive Lung Cancer Patients | Biotech Hunter | Biotech Hunter